


eISBN: 978-1-68108-167-0  
ISBN: 978-1-68108-168-7

eISSN: 2352-9458  
ISSN: 2352-944X

# FRONTIERS IN COMPUTATIONAL CHEMISTRY

(VOLUME 3)



Editors:  
Zaheer Ul-Haq  
Jeffrey D. Madura

Bentham  Books

# **Frontiers in Computational Chemistry**

*(Volume 3)*

**Edited by**

**Dr. Zaheer Ul-Haq**

*Panjwani Center for Molecular Medicine & Drug Research  
International Center for Chemical & Biological Sciences  
University of Karachi  
Pakistan*

**&**

**Dr. Jeffry D. Madura**

*Department of Chemistry & Biochemistry  
Center for Computational Sciences Duquesne University  
Pittsburgh  
USA*

## **Frontiers in Computational Chemistry**

*Volume # 3*

Editors: Dr. Zaheer Ul-Haq and Dr. Jeffry D. Madura

eISSN (Online): 2352-9458

ISSN (Print): 2352-944X

eISBN (Online): 978-1-68108-167-0

ISBN (Print): 978-1-68108-168-7

©2017, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

First published in 2017.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.org](mailto:permission@benthamscience.org).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
  - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
  - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

#### **Bentham Science Publishers Ltd.**

Executive Suite Y - 2  
PO Box 7917, Saif Zone  
Sharjah, U.A.E.  
Email: [subscriptions@benthamscience.org](mailto:subscriptions@benthamscience.org)



# CONTENTS

PREFACE .....	i
LIST OF CONTRIBUTORS .....	iii
<b>CHAPTER 1 IN SILICO APPROACHES FOR DRUG DISCOVERY AND DEVELOPMENT .....</b>	<b>3</b>
<i>Vj qo cu'Ngapctf 'Lqgrj . 'Xli pgij y ctcP'Pco cukxc{co . 'Xcucpj cpcvj ep'Rqqpi cxcpc'o 'and 'Ukpkxcuctci j cxcP Mcppcp</i>	
<b>1. INTRODUCTION .....</b>	<b>3</b>
<b>2. COMPUTER AIDED DRUG DESIGN STRATEGIES .....</b>	<b>5</b>
2.1. Ligand Based Drug Discovery .....	6
2.2. Structure Based Drug Discovery .....	8
<b>3. TOPICS IN CADD .....</b>	<b>9</b>
3.1. Databases .....	10
3.1.1. <i>Small Molecule Databases</i> .....	10
3.1.2. <i>Preparation of Ligand Libraries</i> .....	10
3.1.3. <i>Virtual Combinatorial libraries</i> .....	12
3.1.4. <i>Representation of Small Molecules</i> .....	12
3.1.5. <i>Molecular Descriptors/Features</i> .....	13
3.2. Target Databases for Computer-Aided Drug Design .....	13
3.3. Similarity Searches .....	14
3.4. Quantitative Structure-Activity Relationship (QSAR) .....	16
3.4.1. <i>Classical QSAR (1D/2D)</i> .....	17
3.4.2. <i>3D-QSAR</i> .....	18
3.4.3. <i>Multidimensional QSAR</i> .....	19
3.5. Pharmacophores .....	20
3.6. Comparative Modeling .....	22
3.7. Binding Site Detection and Characterization .....	22
3.8. Protein – Ligand Docking .....	23
3.8.1. <i>Molecular Docking Methods</i> .....	27
3.8.2. <i>Protein Flexibility in Docking</i> .....	31
<b>4. MOLECULAR DYNAMICS SIMULATIONS IN DRUG DISCOVERY AND DESIGN .....</b>	<b>32</b>
4.1. MD Simulations .....	33
4.2. Refinement of Homology Models .....	34
4.3. Combining Docking and MD Simulations .....	35
4.3.1. <i>Receptor Conformation (Preparation of Receptor Structure)</i> .....	35
4.3.2. <i>Ensemble Generation</i> .....	36
4.3.3. <i>Refinement of Docked Complexes</i> .....	37
4.4. Free Energy Calculations .....	38
<b>5. ASSESSMENT OF ABSORPTION DISTRIBUTION METABOLISM EXCRETION AND TOXICITY PROPERTIES .....</b>	<b>40</b>
5.1. Drug Attrition in the Drug Development Phase .....	41
5.2. Compound Library Filters .....	41
5.3. Drug Metabolism: Cytochrome P450 .....	43
5.4. Prediction of Human Ether-A-Go-Go Related Gene Binding .....	45
<b>6. PROTEIN – PROTEIN INTERACTIONS AS DRUG TRAGETS .....</b>	<b>46</b>
6.1. Peptide and Peptidomimetics as ppi Inhibitors .....	47
<b>CONFLICT OF INTEREST .....</b>	<b>49</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>50</b>
<b>REFERENCES .....</b>	<b>50</b>

<b>CHAPTER 2 COMPUTATIONAL CHEMISTRY ASSISTED DESIGN AND SCREENING OF LIGAND-SOLVENT SYSTEMS FOR METAL ION SEPARATION</b> .....	75
<i>Uth'0'0 wuj ct ch'Crk' Cpht' Dqf c.' Cij kuj 'Mwo ct' Upi j c' Fgd.' Rqqlc' Uej w' h' and' M'ncupne' Vtkk' hnt co' Uj gpq{</i>	
<b>1. INTRODUCTION</b> .....	76
<b>2. COMPUTATIONAL METHODOLOGY</b> .....	77
2.1. Moller-Plesset Perturbation Theory .....	78
2.2. Couple Cluster Method .....	79
2.3. Density Functional Theory (DFT) .....	81
2.4. Local Density Approximation .....	82
2.5. Generalized Gradient Approximation .....	83
2.6. Conductor Like Screening Model (COSMO) .....	84
2.7. Basis Set Superposition Error (BSSE) .....	85
2.8. Present Approach of Design and Evaluation .....	85
2.8.1. Evaluation of Structural Parameters .....	86
2.8.2. Evaluation of Interaction Parameters .....	86
2.8.3. Evaluation of Thermodynamic Parameters .....	87
2.8.4. Calculation of Separation Parameters .....	88
<b>3. STRUCTURES AND STRUCTURAL PARAMETERS</b> .....	89
3.1. Microsolvation of Metal Ions .....	89
3.2. Coordination Number and Radial Distribution Function .....	91
3.3. Macrocyclic Crown Ethers .....	94
3.4. Cavity Size of the Host Crown Ethers .....	95
3.5. Tuned Extended Crown Ethers .....	101
3.6. Conformation .....	101
3.7. Donors .....	103
3.8. Calix-Crown Ethers .....	106
3.9. Organophosphorus Ligands .....	111
3.10. Diglycolamide Ligands .....	112
3.11. Carbon Nanotube Functionalized Diglycolamic Acids .....	116
3.12. Ionic Liquids .....	118
<b>4. INTERACTION PARAMETERS -BINDING ENERGY</b> .....	121
4.1. Cavity Dependence .....	123
4.2. Conformer Dependence .....	126
4.3. Donor Atom Dependence .....	127
4.4. Binding Interaction towards Calix-Crown Ethers .....	128
4.5. Binding Interaction with Organophosphorous Ligands .....	130
4.6. Binding Interaction with Diglycolamide Ligands .....	131
4.7. Binding Interaction with CNT-DGA .....	132
<b>5. THERMODYNAMIC PARAMETERS - ENTHALPY, ENTROPY AND FREE ENERGY</b> .....	132
5.1. Free Energy of Extraction using Thermodynamical Cycle for Cs+ .....	135
5.2. Free Energy of Extraction with TMDGA .....	137
5.3. Free Energy of Extraction using Thermodynamical Cycle with TMDGA .....	139
5.4. Free Energy of Extraction with CNT-DGA .....	141
5.5. Free Energy of Extraction using Thermodynamical Cycle .....	144
<b>6. SEPARATION PARAMETERS -PARTITION COEFFICIENTS</b> .....	145
6.1. Dual Mode of Extraction for Cs+ and Na+ Ions in Ionic Liquids .....	148
<b>7. STRUCTURAL AND DYNAMICAL PROPERTIES AT LIQUID-LIQUID INTERFACE</b> .....	152
7.1. Simulation Methodology .....	153
7.2. Hydration Structure of DB18C6/Li+ Complex in Water .....	155
7.3. Dynamic Behaviour of DB18C6/Li+ Complex in Water .....	156
7.4. Effect of Solvents on the Cation Shielding from Solvent and Relative Stabilities .....	158

7.5. Dynamics of Li+ and DB18C6 at Interface .....	161
<b>CONCLUDING REMARKS</b> .....	164
<b>CONFLICT OF INTEREST</b> .....	165
<b>ACKNOWLEDGEMENTS</b> .....	165
<b>REFERENCES</b> .....	165
<b>CHAPTER 3 MOLECULAR MECHANISMS OF CELLULAR TRANSPORT, RESISTANCE AND CYTOTOXIC SIDE EFFECTS OF PLATINUM AND ADJUVANT ANTI-CANCER DRUGS – A MOLECULAR ORBITAL STUDY</b> .....	185
<i>ErHqtY OHqi</i>	
<b>OBJECTIVES</b> .....	186
<b>1. INTRODUCTION</b> .....	186
1.1. Cytotoxic Side Effects .....	189
1.1.1. Factors that Determine Cytotoxic Side Effects .....	192
1.2. Resistance to Pt Drugs .....	203
1.3. Reversal of Resistance to Pt Drugs .....	208
1.4. Changes to Cell Membranes as a Basis for Reduced Accumulation of Pt in Resistant Cells .....	214
1.5. Combinatorial Chemotherapeutic Regimes .....	218
<b>2. RESULTS AND DISCUSSION</b> .....	220
2.1. Cytotoxic Side Effects .....	220
2.2. Resistance to Pt Drugs .....	230
2.3. Reversal of Resistance to Pt Drugs .....	233
2.4. Combinatorial Regimes and Adjuvant Drugs used with Pt Drugs .....	239
<b>3. COMPUTATIONAL MOLECULAR ORBITAL METHODS</b> .....	240
<b>CONCLUSION</b> .....	242
<b>CONFLICT OF INTEREST</b> .....	244
<b>ACKNOWLEDGEMENTS</b> .....	244
<b>REFERENCES</b> .....	244
<b>CHAPTER 4 ELUCIDATING ALLOSTERIC COMMUNICATIONS IN PROTEINS VIA COMPUTATIONAL METHODS</b> .....	260
<i>Dwt cniCrwngpv'and\ OPgxpT gt gnHpeg</i>	
<b>1. INTRODUCTION</b> .....	261
<b>2. INDUCED FIT VS POPULATION SHIFT PARADIGMS</b> .....	263
<b>3. WHAT IS ALLOSTERICITY?</b> .....	265
<b>4. ELUCIDATING ALLOSTERICITY: COLLECTIVE MOTIONS VS. ENERGY TRANSPORT CHANNELS</b> .....	267
4.1. Graph Theory .....	270
4.2. Elastic Network Models .....	279
4.3. Equilibrium and Non-equilibrium Simulations .....	283
4.4. MC/MD Perturbation Methods .....	286
4.5. Integration of Graph Theory Techniques with Simulation Based Methods .....	289
4.6. Statistical Coupling Analysis .....	292
<b>CONCLUSION</b> .....	293
<b>CONFLICT OF INTEREST</b> .....	295
<b>ACKNOWLEDGEMENTS</b> .....	295
<b>ABBREVIATIONS</b> .....	295
<b>REFERENCES</b> .....	297
<b>CHAPTER 5 INFORMATION-THEORETIC REPRESENTATION OF THE CHEMICAL SPACE OF MANY ELECTRON SYSTEMS</b> .....	310
<i>TQQGus wxgn'WNsr gl/Tquc.'O OQ qhpc/Gur fl kw:'EQUtkcpq/Eqt gc.'LEOCpi wny'and'LEOF gj guc</i>	
<b>1. INTRODUCTION</b> .....	311



<b>2. INFORMATION-THEORETICAL MEASURES</b> .....	315
<b>3. INFORMATION-THEORETIC CHEMICAL SPACE FOR MANY ELECTRON SYSTEMS</b> .....	318
<b>4. CHEMICAL SPACE OF SELECTED BACTERIOSTATIC SULFONAMIDES</b> .....	325
<b>5. PREDOMINANT INFORMATION QUALITY SCHEME FOR THE ESSENTIAL AMINO ACIDS</b> .....	331
<b>CONCLUSION</b> .....	344
<b>DISCLOSURE</b> .....	346
<b>CONFLICT OF INTEREST</b> .....	346
<b>ACKNOWLEDGEMENTS</b> .....	346
<b>REFERENCES</b> .....	346
<b>SUBJECT INDEX</b> .....	354

## PREFACE

The branch of chemistry that uses computers to study chemical questions is known as Computational Chemistry which is a very diverse field spanning from the development and application of linear free energy relationships (*e.g.* QSAR, QSPR), to electronic structure calculations, molecular dynamics simulations, and to solving coupled differential equations (*e.g.* drug metabolism). The focus of *Frontiers in Computational Chemistry* is to present material for the application of computational techniques used in biological processes. Topics falling under this umbrella include computer aided molecular design, drug discovery and development, lead generation, lead optimization, database management, computer and molecular graphics, and the development of new computational methods or efficient algorithms for the simulation of chemical phenomena including the analysis of biological activity. In this third volume, we have collected five different perspectives on the application of computational methods towards drug design.

Chapter 1 “*In Silico* Approaches for Drug Discovery and Development” reviews the main computational tools used in the drug discovery process. Joseph, *et al.* also presented the application of physics-based methods that are currently being developed and applied to the drug discovery process.

The removal of toxic metal ions from nuclear and chemical waste streams is an imperative and demanding problem. In Chapter 2 “Computational Chemistry Assisted Design and Screening of Ligand-Solvent Systems for Metal Ion Separation” Ali *et al.* review electronic structure methods to aid the design and development of new ligands that can be used to extract metal ions from the environment. The goal is to use electronic structure methods to identify a suitable ligand anchored on a solid matrix that can be used in a complex separation process.

One challenge in the biochemical field is understanding the side effects of anti-cancer drugs containing platinum. The authors of Chapter 3 “Molecular Mechanisms of Cellular Transport, Resistance and Cytotoxic Side Effects of Platinum and Adjuvant Anti-cancer Drugs — A Molecular Orbital Study” present a review of the application of electronic structure methods to understand the side effects, acquired resistance, and combination of platinum drugs with adjuvant drugs in treating cancer.

In Chapter 4 “Elucidating Allosteric Communications in Proteins *Via* Computational Methods”, the authors present a review of the application of different normal mode analyses based on molecular dynamics methods to understanding allosteric communication in proteins. Alakent and Ince also present the application of graph theory, perturbation methods, and

*ik*

statistical methods to investigate allosteric mechanisms.

The authors of Chapter 5 “Information-theoretic chemical space for many electron systems: from atoms to biological and pharmacological molecules” review the utility of an information-theoretic three-dimensional (IT-3D) space to unveil the unique physical, chemical and biological aspects of a great diversity of many electron systems. These multiple electrons systems range from simple atomic systems to more complex systems such as amino acids. Esquivel *et al.* claim that “All chemical families recognized by the existing energy-based classifications are embraced by this entropic scheme”.

**Zaheer Ul Haq**

Panjwani Center for Molecular Medicine & Drug Research  
International Center for Chemical & Biological Sciences  
University of Karachi  
Pakistan

**&**

**Jeffry D. Madura**

Department of Chemistry & Biochemistry  
Center for Computational Sciences Duquesne University  
Pittsburgh  
USA

## List of Contributors

<b>Anil Boda</b>	Chemical Engineering Division, Bhabha Atomic Research Centre, Mumbai, India
<b>Ashish Kumar Singha Deb</b>	Chemical Engineering Division, Bhabha Atomic Research Centre, Mumbai, India
<b>Burak Alakent</b>	Department of Chemical Engineering, Bogazici University, Istanbul, Turkey
<b>Clifford W. Fong</b>	Eigenenergy, Adelaide, South Australia, Australia
<b>C. Soriano-Correa</b>	Química Computacional, FES-Zaragoza, Universidad Nacional Autónoma de México, 09230-Iztapalapa, México, D.F, Mexico
<b>J.C. Angulo</b>	Instituto Carlos I de Física Teórica y Computacional, Universidad de Granada, 18071-Granada, Spain Departamento de Física Atómica, Molecular y Nuclear, Universidad de Granada, 18071-Granada, Spain
<b>J.S. Dehesa</b>	Instituto Carlos I de Física Teórica y Computacional, Universidad de Granada, 18071-Granada, Spain Departamento de Física Atómica, Molecular y Nuclear, Universidad de Granada, 18071-Granada, Spain
<b>Kalsanka Trivikram Shenoy</b>	Chemical Engineering Division, Bhabha Atomic Research Centre, Mumbai, India
<b>M. Molina-Espíritu</b>	Departamento de Química, Universidad Autónoma Metropolitana, 09340-México, D.F., México
<b>Pooja Sahu</b>	Chemical Engineering Division, Bhabha Atomic Research Centre, Mumbai, India
<b>R.O. Esquivel</b>	Departamento de Química, Universidad Autónoma Metropolitana, 09340-México, D.F., México Instituto Carlos I de Física Teórica y Computacional, Universidad de Granada, 18071-Granada, Spain
<b>S. López-Rosa</b>	Instituto Carlos I de Física Teórica y Computacional, Universidad de Granada, 18071-Granada, Spain Departamento de Física Aplicada II, Universidad de Sevilla, 41012-Sevilla, Spain
<b>Srinivasaraghavan Kannan</b>	Bioinformatics Institute, A STAR, Singapore 138671,
<b>Sk. Musharaf Ali</b>	Chemical Engineering Division, Bhabha Atomic Research Centre, Mumbai, India
<b>Thomas Leonard Joseph</b>	Bioinformatics Institute, A STAR, Singapore 138671,

*iv*

<b>Vasanthanathan Poongavanam</b>	Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark
<b>Vigneshwaran Namasivayam</b>	Department of Life Science Informatics, B-IT, Rheinische Friedrich- Wilhelms-Universitaet, Dahlmannstr, 2, 53113 Bonn, Germany
<b>Z. Nevin Gerek Ince</b>	Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, USA

# *In Silico* Approaches for Drug Discovery and Development

Thomas Leonard Joseph<sup>1</sup>, Vigneshwaran Namasivayam<sup>2</sup>, Vasanthanathan Poongavanam<sup>3</sup> and Srinivasaraghavan Kannan<sup>1,\*</sup>

<sup>1</sup> Bioinformatics Institute, A\*STAR, Singapore 138671, Singapore

<sup>2</sup> Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universitaet, Dahlmannstr 53113 Bonn, Germany

<sup>3</sup> Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark

**Abstract:** Discovery of new therapeutics is a very challenging, expensive and time-consuming process. With the number of approved drugs declining steadily combined with increasing costs, a rational approach is needed to facilitate, expedite and streamline the drug discovery process. In this regard computational methods are playing increasingly important roles, largely assisted by developments in algorithms and greatly increased computer power. With *in silico* methods playing key roles in the discovery of growing numbers of marketed drugs, nowadays use of computational tools has become an integral part of most drug discovery programs. Computational tools can be applied at different stages: from target selection through identification of hits to optimization. In this chapter we aim to provide an overview of major tools that have been developed and are routinely being used in the search of novel drug candidates. In addition, we present recent advances, especially in the application of physics-based simulation methodologies, in the drug discovery process for the development of improved therapeutics.

## 1. INTRODUCTION

Drug discovery is the process of creating or finding a molecule which has a specific activity on a biological organism. The aim of the discovery process is

---

\* Corresponding author Srinivasaraghavan Kannan: Bioinformatics Institute, A\*STAR, Singapore 138671; E-mail: raghavk@bii.a-star.edu.sg

to identify compounds with pharmacological interest that can be used in the treatment of diseases. As several factors decide the activity of a drug molecule, undoubtedly the development of a new drug is a complex and difficult process. It is estimated that a drug discovery process can cost several hundred million dollars and a typical discovery cycle can take as many as 15 years from the first compound identified in the laboratory until the drug is brought to market [1 - 6]. Traditionally drug discovery starts with an experimental screening of compound libraries of molecule that bind to biomolecular targets and modulate their activity. This is followed by subsequent rounds of iterative chemical modifications to enhance their potency, with further optimization for increased selectivity and pharmacological properties [5, 6]. The emergence of combinatorial chemistry combined with rapid developments in high throughput screening (HTS) technologies have speeded up the discovery process by enabling huge libraries of compounds to be screened in short periods of time [7 - 10]. However the hit rates for high throughput screens are often extremely low and most identified hits do not proceed to actual leads [7 - 10].

The sequencing of human genome has revealed unknown proteins that might serve as new drug targets. However the therapeutic importance of most of these proteins is either unknown or poorly characterized. The routine set of experiments (blind expression, purification and *in vitro* assays) that are typically used, cannot be applied for thousands of proteins against libraries of several hundreds of thousands of compounds. Therefore new approaches are needed to speed up and streamline drug discovery and development process to save time, money and resources. In this regard computational approaches have a major role to play.

A variety of computational approaches can be applied at different stages of the drug-design process; right from target identification and validations, identification of initial hits, hit-to-lead selection, and optimization of leads to avoid safety issues.

In this chapter we aim to provide an overview of major *in silico* tools and approaches that have been developed and are routinely being used to search for novel drug candidates. In addition we will also present recent advances (enhancements), especially the application of physics-based simulation

methodologies that lead to a dynamic view of receptor drug interaction, replacing the traditional dogma of single structure-based drug design with the concept of ensemble-based drug design, where conformational flexibility of a receptor molecule plays key roles.

In the first section, we introduce two major Computer Aided Drug Design (CADD) strategies namely ligand based and structure based methods that are widely used in the drug discovery process. Next we briefly introduce several computational techniques that are routinely used. In the third section we will introduce Molecular Dynamics (MD) simulations and applications at various steps of the drug discovery process. We then discuss computational methods for predictions and optimization of drug metabolism and pharmacokinetics. Finally we will discuss targeting protein-protein interactions and briefly introduce peptide based inhibitor design for inhibitions of protein-protein interactions. The goal here is to offer an overview of highly promising themes and tools in this interdisciplinary field.

## **2. COMPUTER AIDED DRUG DESIGN STRATEGIES**

Drug discovery is an extended and time consuming process, which can take several years to translate a compound into a drug molecule. Therefore development of a drug discovery process with the ability for rapid identification of potential binders to the target of therapeutic interest is of great importance in the biotech and pharmaceutical companies. In this regard computational methods enable rapid screening of huge libraries of pharmacologically interesting compounds for identifying potential binders through modelling and simulation. Strategies for CADD vary depending on the availability of structural and other information regarding the target (enzyme/receptor) and the drug (ligand). Two major modelling strategies “indirect” and “direct” are currently used in the drug discovery process (Fig. 1). In the indirect approach, also known as “Ligand based” the design is based on a comparative analysis of the structural features of compounds with known activity. The direct approach, also known as “Structure based”, utilizes the three-dimensional structural features of the target molecule of interest. We now examine these two in some detail.



## Computational Chemistry Assisted Design and Screening of Ligand-Solvent Systems for Metal Ion Separation

Sk. Musharaf Ali\*, Anil Boda, Ashish Kumar Singha Deb, Pooja Sahu and Kalsanka Trivikram Shenoy

*Chemical Engineering Division, Bhabha Atomic Research Centre, Mumbai, 40085-India*

**Abstract:** Computational chemistry that comprises of Quantum mechanics (QM), Monte-Carlo (MC), molecular dynamics (MD) and *ab initio* MD (AIMD) simulation has emerged as a prospective tool for the calculation of various molecular properties by capturing the complex molecular interactions and is being used extensively in the fields of science and engineering. In that context, design and screening of suitable ligands for efficient separation of metal ions is imperative and demanding in view of the safe removal of metal ions from nuclear and chemical waste stream employing the much practiced separation processes namely: solvent extraction and ion exchange. In solvent extraction, an organic solvent containing one or more ligands and in ion exchange, a solid matrix called stationary phase, the surface of which is decorated by functional group/ligands are widely used to remove the desired metal ions from the aqueous medium.

This chapter will focus on designing new ligands or improving the existing ones for understanding the accurate nature of host-guest interactions together with the bonding nature with respect to the donor atom, complexation thermodynamics, conformational features of the ligands and solvent effect. Computational chemistry can play a crucial role for the quantitative predictions of the structural parameters, coordination number, complexation stability and selectivity of metal ion –ligand complexation with respect to the solvent extraction and ion exchange processes. Use of ionic liquid as a novel and alternative solvent to common organic solvent has also been discussed along with its

---

\* **Corresponding author Sk. Musharaf Ali:** Chemical Engineering Division, Bhabha Atomic Research Centre, Mumbai, 40085-India; Tel: +91-022-25591991; Fax: +91-022-25505151; E-mail: musharaf@barc.gov.in

dual extraction mechanism. Further, how Quantum electronic structure calculation can be fruitfully used for selecting the suitable ligand anchored on a solid matrix for a complex separation process has been demonstrated.

**Keywords:** AIMD, BE, Born-Haber Thermodynamic cycle, Coordination number, COSMO, DFT, Entropy, Free energy, Geometry, Ion exchange, MP2, Partition coefficients, Radial distribution function, Separation factor, Solvent extraction.

## 1. INTRODUCTION

The design of suitable molecular ligands for efficient separation of metal ions is imperative and demanding in view of the secure discarding of nuclear and chemical waste in particular and value recovery of metals in general by means of the available extraction technologies [1, 2]. One of the most regularly used technologies for metal ion separations is the extraction of the metal ions from the aqueous solutions with an organic solvent containing the ligand. From the viewpoint of designing new ligands or improving the existing ones, understanding the accurate nature of ion-ligand interactions together with the binding energies, conformational features of the ligands and solvent effect would be very helpful. In this regard, quantum chemical computational software with the aid of high performance parallel computers plays a crucial role for the quantitative predictions of the stability, structural parameters, selectivity and is being applied fruitfully in the various separation processes.

The power of molecular modelling is growing rapidly with the continuing development of computer power, robust algorithms, and the availability of software [3]. Molecular modelling can provide useful estimates of the properties and behaviour of materials-even before they have been synthesized and useful estimates of the parameters and behaviour needed to do traditional chemical engineering process development and design [4]. From experimental point of view, choosing a suitable solvent/extractant from a myriad of solvents and extractants is a very time consuming and tedious affair. It will be of great help if the screening is done beforehand by means of other less time consuming and easy techniques. Hence, the solubility and partition coefficients of various extractants

with different donor atom, substituent, conformation and type of diluents can be easily estimated.

In this chapter, we have critically evaluated the structures, energetic and thermodynamics of complex solution phase pertaining to solvent extraction and ion exchange processes using varieties of *ab initio* density functional theory and MD simulation with an aim to demonstrate the selection of suitable computational methods for practical metal ion separation process of interest. We mainly focus on the results of our recently studied molecular systems pertaining to the separation of metal ions which are important for nuclear establishment with the aid of different macrocyclic and chelating ligands and ligand functionalized CNTs. We mainly discuss the complexation of ions which are of importance in nuclear technology: *viz.* Lithium, Sodium, Cesium, Strontium, Thorium, Uranium, Plutonium, Zirconium, Hafnium, Europium and Americium with ligand/solvent like crown ether, calix-crown, diglycolamide, DGA functionalized CNT, dodecane, ionic liquid *etc.*

## 2. COMPUTATIONAL METHODOLOGY

There is a wide variety of computational methods starting from semi-empirical to *ab initio*, each having its own merits and demerits in terms of cost, time and accuracy for a particular application [5]. Semiempirical methods can be useful for initial screening of the molecular system of interest [6]. Among *ab initio* methods, though Hartree Fock (HF) is considered to be the cheapest it has some serious limitation due to inability to handle the electron correlation [7]. The Moller Plesset perturbation (MP<sub>n</sub>) [8] and couple cluster singles and doubles (CCSD) [9] methods are quite accurate but heavily expensive and hence can be restricted to small molecular system. However, density functional theory (DFT) [10] based methods, which earlier was considered to be *ab initio* has partly lost its *ab initio* credential due to large number of parameterization of the exchange-correlation functional but still is the work horse for large molecular system. There is a wide variety of DFT functional one can select for a specific interest of application. Similarly, the size of the basis set can be chosen depending on the molecular properties to be evaluated. Clearly, there is a trade off between the functional and size of the basis set depending on the molecular size and chemical properties. In

## Molecular Mechanisms of Cellular Transport, Resistance and Cytotoxic Side Effects of Platinum and Adjuvant Anti-cancer Drugs – A Molecular Orbital Study

Clifford W. Fong\*

*Eigenenergy, Adelaide, South Australia, Australia*

**Abstract:** The side effects, acquired resistance, reversal of resistance, and combination of Pt drugs with adjuvant drugs has been examined using an extensive review of the literature and molecular orbital computations. It is concluded that Pt chemotherapeutic regimes are dominated by side reactions, particularly hydrolysis in blood serum and delivery efficiency. For example, it is shown that transplatin is therapeutically inactive because it hydrolyses faster in blood serum than cisplatin, so little transplatin reaches its target DNA. The reactivity of charged hydrolysis products determines the severity of side effect. The reactivity determining properties of the approved Pt drugs and their various hydrolysed species are calculated. The cellular uptake of Pt and adjuvant drugs is fastest for neutral species, with high lipophilicity, since their desolvation penalties for crossing the cell membrane are lowest. Pt resistant cell lines generally have lower levels of drug uptake, indicating this is a dominant first order cause of cellular resistance. Resistance can be caused by complexation of charged Pt species to phosphatidylserine (PS) headgroups, or by Pt complexation to the inner terminii of the trans-membrane pore of the hCtr1 transporter. Drugs that are known to reverse induced Pt resistance can decomplex the Pt-PS or Pt-hCtr1 complexes, restoring normal PS or hCtr1 functions. Molecular biophysical properties of adjuvant drugs used in combination with Pt drugs (*e.g.*, paclitaxel, doxorubicin, gemcitabine, Folfox) can assist the clinical evaluation of combinatorial Pt based chemotherapeutic regimes. These drugs have similar properties to the approved Pt drugs, and fit into the same “therapeutic window” in terms of their likely cellular uptakes and reduction

---

\* Corresponding author Clifford W. Fong: Eigenenergy, Adelaide, South Australia, Australia; E-mail: cwfong@internode.on.net

potentials. The role of free radical species involved in Pt drug induced apoptosis *via* electron transfer from the guanine base of DNA, and the reactions of oxidizing hydroxyl radicals and reducing hydrated electrons reactions with cisplatin, transplatin and carboplatin under physiological pH and Cl<sup>-</sup> ion condition have been examined.

Free radical sensitisers such as TMPD and TETA when combined with Pt drugs may allow targeting of the more hypoxic environments in solid cancerous tumours (and less damage to normal cells). The calculated biophysical parameters ionization energy and electron affinity, which are related to the redox environments found in cells, may be useful predictors of likely cytotoxic efficacy of combination therapies involving sensitisers and Pt drugs.

**Keywords:** Adjuvant drugs, Anti-cancer, Cellular uptake, Combinatorial chemotherapies, Platinum drugs, Resistance, Reversal of resistance, Side effects.

## OBJECTIVES

*Cytotoxic side effects of antineoplastic chemotherapeutic Pt drugs:* to examine biophysical molecular properties that could be used to predict the propensity of Pt drugs to cause unwanted side effects.

*Resistance to Pt drugs:* to examine mechanisms involved in acquired resistance, particularly the cellular accumulation mechanisms: (a) passive diffusion, active transport including copper transporters, organic cation transporters; (b) active efflux and intracellular reductive processes.

*Reversal of platinum resistance:* to develop predictive criteria for drugs that can reverse acquired resistance.







*Combination of Pt chemotherapy with other adjuvant anti-tumour drugs and sensitisers:* to develop predictive criteria that may serve to guide overall therapeutic efficacy.

## 1. INTRODUCTION

Chemotherapy, surgery and radiation are the main treatments for cancer. Platinum chemotherapeutics are the most widely prescribed drugs in modern oncology (administered to about 50 % of all cancer patients), either alone or in combination

with other anti-cancer drugs and/or radiation therapy. Platinum drugs are used for the treatment of a broad spectrum of specific cancers, including testicular, ovarian, bladder, head and neck, esophageal, small and non-small cell lung, breast, cervical, stomach and prostate cancers, as well as Hodgkin's and non-Hodgkin's lymphomas, neuroblastoma, sarcomas, multiple myeloma, melanoma, and mesothelioma. One of the greatest successes in chemotherapeutics was the advent of cisplatin treatment of metastatic testicular cancer where the survival rate in 1970 was about 5% of young men, whereas now greater than 80% of such cases are cured [1].

**Table 1. Structure and clinical properties of approved Pt anti-cancer drugs.**

	Molecular formula and structure	Dose-limiting toxicity	Clinical status and indications
Cisplatin	$H_6Cl_2N_2Pt$ 	Nephrotoxicity	Approved worldwide (sarcomas, small cell lung cancer, ovarian cancer, lymphomas, and germ cell tumors)
Carboplatin	$C_6H_{12}N_2O_4Pt$ 	Myelosuppression	Approved worldwide (ovarian carcinoma, lung, head and neck cancers)
Oxaliplatin	$C_8H_{14}N_2O_4Pt$ 	Neurotoxicity	Approved worldwide (colorectal cancer, advanced gastric and ovarian cancers)
Nedaplatin	$C_2H_8N_2O_3Pt$ 	Myelosuppression	Approved in Japan (head and neck, lung small cell, bladder, ovary, esophagus and cervix cancer)
Heptaplatin	$C_{11}H_{20}N_2O_6Pt$ 	Nephrotoxicity, intra-abdominal bleeding	Approved in Korea (gastric cancer)
Lobaplatin	$C_9H_{18}N_2O_3Pt$ 	Thrombocytopenia	Approved in the People's Republic of China (chronic myelogenous leukemia, inoperable, metastatic breast, small cell lung cancer)

## Elucidating Allosteric Communications in Proteins via Computational Methods

Burak Alakent<sup>1,\*</sup> and Z. Nevin Gerek Ince<sup>2</sup>

<sup>1</sup> Department of Chemical Engineering, Bogazici University, Istanbul, Turkey

<sup>2</sup> Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, USA

**Abstract:** Cellular functions are primarily facilitated by biomolecular interactions with proteins, and ligand binding synchronizes the function of a protein to the requirements of its surroundings. Consequences of ligand binding to a protein may range from subtle perturbations in the side chain conformations in the vicinity of the binding region to large-scale global conformational changes. Coupling of a change in conformation with that in activity of a protein is traditionally referred to as allostery. In the recent years, however, the conventional allostery concept has been challenged to include perturbations in dynamics of a large number of proteins even in the absence of detectable changes in their backbone structure. Although it can evidently be suggested that binding produces a signal which can propagate to distant sites of a protein to achieve the observed conformational and/or dynamical perturbations, revealing a detailed mechanism of signal propagation is still an elusive task. In order to elucidate this mechanism, the following two questions demand to be answered: i) How do different regions of the protein respond? ii) How does the protein “sense” and transmit the local perturbation? The former question, being relatively easier to handle, has been tackled with Normal Mode Analysis (NMA), Elastic Network Models (ENMs), and statistical analyses of Monte Carlo (MC) and Molecular Dynamics (MD) simulation trajectories for the last ~30 years in the literature. The latter question, on the other hand, is currently a hot research topic in research community. Allosteric signals are generally suggested to propagate through “energy transport channels” (residue networks, or signaling pathways) formed by bonded and nonbonded contacts of residues, and experimental methods, such as double-mutant analysis and NMR relaxation methods, are used to identify residues participating to these intraprotein signaling pathways. For the last 10-15 years, there has been a tremendous interest in

---

\* **Corresponding author Burak Alakent:** Department of Chemical Engineering, Bogazici University, Istanbul, Turkey; Tel: +90 212 359 6433; E-mail: burak.alakent@boun.edu.tr

utilizing computational techniques to elucidate allostERICITY in proteins. While elastic network models and molecular simulations have continued to be resourceful methods, the most important novel contributions, presumably, have come from the graph theory, perturbation methods, and the statistical coupling method. In this chapter of *Frontiers in Computational Chemistry*, various computational techniques used to elucidate allosteric mechanisms in proteins are to be discussed with various examples.

**Keywords:** Conformational change, Communication pathway, Crystal structure, Database, Elastic network model, Frequency, Graph theory, Induced fit, Information theory, Ligand binding, Molecular dynamics, Monte carlo simulation, Perturbation, Population shift, principal component analysis, protein dynamics, residue network, Signal propagation, Statistical coupling analysis, Web-server.


## 1. INTRODUCTION

Although the relation between protein structure and dynamics has long been established, one of the leading roles in replacing the static view of the protein with a “dynamic machine” paradigm has been played by computer modelling and simulations performed since 1980s. In two independent and simultaneous pioneering computational studies [1, 2], Normal Mode Analysis (NMA) was employed on the energy minimized crystal structure of bovine pancreatic trypsin inhibitor, and the resulting eigenvectors (modes) were found to be consistent with the directions of collective fluctuations. It is interesting to note that even in these earliest studies, the paradox between the harmonicity assumption of NMA, *i.e.* protein oscillates harmonically around a single minimum, and the existence of anharmonic motions particularly at low frequency modes was well recognized. Since then, these two “contradictory” views have been simultaneously and widely accepted in the literature, and a compromise has been aimed to be attained *via* various models.

Recognizing the multimimum architecture of the protein energy landscape has been an important step in deciphering protein dynamics. In a leading study, experimental and modelling work on the binding of CO to myoglobin showed that protein dynamics evolve within conformational substates and cannot be explained by simple exponentials and Arrhenius kinetics [3]. The “rugged” energy landscape of myoglobin dictating its dynamics was described by a hierarchical



organization of “tier”s: Tier 0 conformations were suggested to correspond to three distinct orientations of the bound CO with respect to the heme group, while conformations at higher tiers, which stemmed from one of the conformations at the lower tier, were much greater in number and demanded a statistical treatment [4]. Molecular Dynamics (MD) simulations helped to clarify the issue to a certain extent. Structures separated by a time interval of  $>0.15\text{-}0.20$  ps during the MD simulation of myoglobin at 300 K were observed to converge into different energy minima, and the multi minimum protein energy surface sampled during the simulation was suggested to be characterized by the conformational changes of the loop regions and rigid body motions of  $\alpha$ -helical segments [5]. MD simulations also showed that the coupled local and global motions have essentially a nonlinear character, consisting of nonperiodic transitions between multiple minima [6]. Schematic representations of NMA and multimimum models of the protein free energy landscape are shown in Fig. (1).



**Fig. (1).** Energy landscape of a protein viewed by two different models: **(A)** NMA: Harmonic fluctuations around a single minimum **(B)** Transitions between multiple minima: Here, Tier 0 corresponds to the whole “valley”, while Tier 1 minima correspond to each local minimum.

A compromise between the description of NMA, MD simulations and functional protein dynamics has been reached by a combination of experimental and computational studies. Vibrational motions in fs-ps scale (fast dynamics) determined by NMA, and the inter-minima transitions known to have functional importance (slower dynamics) determined by experimental studies were shown to be in agreement for ubiquitin [7] and adenylate kinase (ADK) [8], while MD

## Information-Theoretic Representation of the Chemical Space of Many Electron Systems

R.O. Esquivel<sup>a,b,\*</sup>, S. López-Rosa<sup>b,c</sup>, M. Molina-Espíritu<sup>a</sup>, C. Soriano-Correa<sup>d</sup>, J.C. Angulo<sup>b,e</sup> and J.S. Dehesa<sup>b,e</sup>

<sup>a</sup> Departamento de Química, Universidad Autónoma Metropolitana, 09340-México, CDMX, México

<sup>b</sup> Instituto Carlos I de Física Teórica y Computacional, Universidad de Granada, 18071-Granada, Spain

<sup>c</sup> Departamento de Física Aplicada II, Universidad de Sevilla, 41012-Sevilla, Spain

<sup>d</sup> Química Computacional, FES-Zaragoza, Universidad Nacional Autónoma de México, 09230-Iztapalapa, México, CDMX, México

<sup>e</sup> Departamento de Física Atómica, Molecular y Nuclear, Universidad de Granada, 18071-Granada, Spain

**Abstract:** In this chapter we review the utility of an information-theoretic three-dimensional (IT-3D) space to unveil the unique physical, chemical and biological aspects of a great diversity of many electron systems, ranging from neutral and ionized atomic systems and simple molecules to much more complex ones such as amino-acids and pharmacological molecular ensembles. This space is generated from the Shannon entropy, the Fisher information and the disequilibrium measures along with their corresponding Fisher-Shannon and López-Ruiz-Mancini-Calvet (LMC) complexity measures. To achieve it we start from the theoretical ground that atoms and molecules can be described by means of the basic information-theoretical notions of delocalization, order, uniformity and complexity; thus, revealing the possible existence of an universal three-dimensional information-theoretic space for all systems in Nature. On the other hand, we discuss the abilities of the Shannon entropy, Fisher information and disequilibrium to capture the spatial spreading features of delocalizability, order and uniformity of biological molecules. Indeed, these three entropic measures are

\* **Corresponding author R.O. Esquivel:** Departamento de Química, Universidad Autónoma Metropolitana, 09340-México, D.F., México; Tel/Fax: +525558044675; E-mail: esquivel@xanum.uam.mx

found to uniquely characterize all amino acids, and some selected pharmacological systems, through a predominant information-theoretic quality scheme (PIQS) which gathers all chemical families by means of three major spreading features: delocalization, narrowness and uniformity. This scheme is shown to recognize 4 chemical groups characterized by this entropic scheme: delocalized (aliphatic and aromatic), narrowed (electro-attractive) and uniform (tiny). Chemical groups are differentiated according to their energy classifications. Also, it is shown that information planes produce interesting patterns associated to the PIQS scheme.

## 1. INTRODUCTION

Most physical theories pursue to describe the most basic aspects of the macroscopic world through simple models, predicting some parameters that are assumed or taken from experiments. In consequence, the prediction of these parameters cannot be predicted by simple theoretical models. Obviously, to gain insight of all physical features requires to analyse the features of the systems in smaller scales where the simplest processes correspond to the lowest level of knowledge. It is advantageous to go to a deeper level since it reduces the number of unspecified parameters, and hence the corresponding theory is considered to be complete and fairly adequate. A typical example of this kind of theories is Molecular Biology which is ultimately based on quantum chemistry and molecular dynamics. Notwithstanding that more comprehension of the lower level is achieved, it is practically impossible to attain a full description of the molecular processes taking place in living systems, hence the intricacy of the large set of parameters makes the endeavour a very difficult one. Considering an alternative approach to extracting the essential features of biological processes by use of Information Theory (IT) concepts has proven to be a succesful one. Moreover, the rapidly evolving field of Quantum-information biology [1 - 3], which employs information-theoretic concepts, is gaining wide attention to comprehend some of the most basic and yet unsolved questions of molecular biology.

There has been an increasing interest in characterizing and classifying different physical systems in terms of a few fundamental properties, not only in Physics but also in Chemistry and Biology. Perhaps, quantitative structure activity relation (QSAR) and quantitative structure properties relation (QSPR) constitute the most commonly approaches employed to relate molecular structures with physical

properties and biological activity. The beginning of these techniques could be remounted to mid 60's of the last century, when Hansch and Fujita proposed a connection between biological activity and chemical structure [4]. Furthermore, they argued that similar molecules share similar solubility, expecting that the relative polarity of molecules could be crucial in order to find a parameter relating structure and activity. Based on the ideas of Robert Muir and the Hammett equation [5], the structural changes might be correlated by means of parameters allusive with the partition coefficient to numerically analyse structure-activity problems [6] of biomolecules. Consequently, QSAR has evolved from simple regression methods to the analysis of very large sets of data comprising thousands of diverse molecular structures, and uses a wide variety of statistical and machine learning techniques. These advances have found broad application on QSAR methods in chemistry, material and nano-material, and life sciences to assess potential impacts on ecological systems [7]. One of the most promising application of this methodology resides in the chemical space [8]. The concept of chemical space emerges as a metaphor, and suggests the existence for a chemical universe which contains millions of organic compounds [9]. Although chemical space has not been well defined, it considers a multidimensional descriptor space in the sense of a region defined by a particular choice of descriptors to characterize as many chemical compounds as possible, and relate similar molecular structures with desired physicochemical properties and biological activity. In that respect, the relevance of any region of the chemical space must be judged by its ability to group compounds with similar bioactivity together [10].

The large number of physicochemical properties to be chosen as descriptors of the chemical space is an important disadvantage, due to the risk of employing irrelevant and redundant descriptors. Moreover, different systems could be wrongly misplaced at the same point of such a space if the descriptors selection is not well chosen [7]. A deeper understanding of this vast set of molecules will advance our knowledge of biological processes; therefore, the development of a systematic and rational classification of the chemical space is crucial for the progress of chemical applications. The analysis and exploration of this space represents a highly demanding computational task due to the immense number of possible stable molecules [11]. This challenge has led to several sophisticated

## SUBJECT INDEX

**A**

Ab initio molecular dynamics (AIMD) 75, 76, 91, 93  
 Acid 326, 327, 328, 339, 340, 341  
   aspartic 340, 341  
   glutamic 339, 340, 341  
   p-aminobenzoic 326, 327, 328  
 Acquired cisplatin resistance 209, 211  
 Acquired resistance 185, 186, 188, 203, 204, 210, 225, 230, 233  
 Actinide ions 92  
 Active conformations 7, 264, 265, 284  
 Adjuvant drugs 185, 186, 218, 239, 240  
 Adjuvant non-Pt drugs 239, 243  
 ADMET properties 40, 41  
 AIMD simulation 91, 92, 93, 122, 164  
 Alanine 339, 340, 341  
 Algorithms 9, 26, 27, 28, 29  
   genetic 26, 27, 28, 29  
   protein–ligand docking 9  
 Alkanes 321, 323, 324, 325  
 Allosteric communications 267, 268, 269, 275, 283, 286, 290, 291, 294, 295  
 Allostericity 265, 266, 267, 268, 272, 279, 281, 290, 292, 293  
 Allosteric pathways 268, 269, 270, 279, 290, 292, 294  
 Allosteric pockets 281, 282  
 Allosteric proteins 266, 267, 271, 276, 281  
 Allosteric transitions 279  
 Amino acids, essential 331, 332, 334, 337, 346  
 Amino acids (AA) 48, 270, 271, 276, 311, 315, 319, 321, 324, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 343, 344, 345  
 Amino acid structures 334, 337  
 Anisotropic network model (ANM) 269, 280, 296  
 Anti-cancer drugs 187, 193, 194, 201, 221  
 Apoptosis 189, 202, 203, 210, 216, 217, 218, 219, 240, 242  
 Approximations, generalized gradient 82, 83, 84, 91  
 Aqueous environments 142, 220, 225, 227

Atomic units 320, 322, 323, 328, 330, 336

**B**

Bacteriostatic activity 325, 326, 327, 344, 345  
 Basis function 96, 97, 104, 120, 123, 124, 128  
 Basis set superposition error (BSSE) 85, 124, 126  
 Binding affinities 24, 29, 30, 31, 38, 44  
 Binding energies 28, 29, 33, 40, 76, 78, 125, 128, 130, 131, 263  
 Binding enthalpy 134, 135  
 Binding enthalpy order 135  
 Binding interaction 129, 130, 131, 132, 225  
 Binding sites 8, 9, 19, 20, 23, 28, 264, 279, 282  
   putative 9, 23  
   small molecule 8, 23  
 Biological activity 7, 16, 17, 18, 30, 40, 312  
 Biology, molecular 311  
 Biomolecular interactions 260, 263  
 Biotransformations 44, 191  
 Blood plasma 189, 193, 194, 195, 196, 197, 198, 199, 200, 207, 215, 216, 220, 226, 227, 229, 230, 231, 233, 236, 242  
 Blood serum 185, 190, 192, 198, 199, 220, 225, 229, 232, 242  
 Bond distance 92, 99, 100, 102, 103, 105, 106, 107, 109, 112, 114, 116, 118, 121, 125, 143, 153  
 Bond length 91, 101, 104, 105, 109, 117, 154  
 Born-haber thermodynamic cycle 76, 143, 164, 165

**C**

Calculated bond distance of Sr 100  
 Calculated structural parameters 97, 99, 108, 110, 111, 112, 113, 114, 115, 117, 119  
 Calculated structure of Sr- 102, 103  
 Calculated value of thermodynamic parameters 139, 140, 144  
 Calculations, protein-ligand binding affinity 39  
 Calix-crown ligands 107, 130  
 Cancer cells 188, 210, 218, 220, 233, 238

- Carboplatin 186, 188, 190, 191, 192, 196, 197, 198, 199, 201, 205, 206, 212, 217, 218, 219, 224, 226, 227, 238, 240, 244
- Carboplatin and oxaliplatin 188, 189, 192, 196, 205, 206, 217, 227
- CCSD values 122
- Cell lines 192, 194, 196, 198, 200, 205, 207, 208, 217, 233, 234
- Cell membrane 185, 192, 197, 198, 200, 204, 207, 208, 211, 214, 215, 216, 220, 221, 226, 229, 230, 231, 232, 233, 234, 235, 237, 238, 239, 242, 243
- Charged Pt hydrolysis species 232, 234, 236
- Cisplatin 185, 186, 188, 189, 190, 191, 192, 196, 197, 198, 199, 200, 201, 202, 204, 205, 206, 207, 208, 209, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 224, 225, 226, 227, 228, 229, 230, 232, 233, 234, 236, 237, 238, 240, 242, 244, 277
- aquated form of 215, 236
  - combination of 213, 218
  - hydrolysis of 189, 197, 198, 219
  - hydrolysis products of 227
  - uptake of 196, 215, 232
  - uptake transporter of 201
- Cisplatin and carboplatin 191, 192, 198, 199, 206, 226, 240
- Cisplatin exposure 201, 205
- Cisplatin-induced nephrotoxicity 188, 214
- Cisplatin-phosphatidylserine 215, 236
- Cisplatin resistance 204, 205, 208, 209
- Cisplatin-resistant cells 201, 205, 206
- Cisplatin treatment 187, 211
- Combinatorial chemotherapies 186
- Complexed species 235
- Complexes 23, 30, 31, 33, 38, 94, 107, 110, 114, 115, 117, 118, 119, 141, 143, 213, 218, 228, 229, 232, 237, 240, 243
- docked protein–ligand 38
  - ligand–protein 38
  - metal ion-diglycolamide ligand 115
  - metal ion-ligand 107
  - multiple protein–ligand 33
  - structures of 23, 117
- Complex formation 25, 31, 33, 87, 142, 155, 163, 164, 215, 236
- Complexity 13, 15, 31, 35, 36, 151, 276, 310, 313, 314, 318, 321, 330, 331, 344
- definitions of 314
- Complexity measures 310, 313, 317, 319, 324, 329
- Computational tools 3, 36, 43, 45
- Computer aided drug design (CADD) 5, 9
- Concepts, information-theoretic 311, 344, 345
- Conformational entropy 19, 39
- Conformational flexibility 5, 11, 21, 32
- Conformational space 21, 25, 36
- Conformational states 266, 285
- Conformational transitions 280, 285, 286, 293
- Conformations 19, 27, 28, 29, 32, 35, 37, 48, 49, 77, 94, 102, 107, 159, 260, 262, 263, 264, 265, 266, 273, 274, 275, 278, 280, 281, 286, 289, 334, 335, 345
- minimized 273, 274
  - populated 263
  - possible 28
- Constraint network analysis (CNA) 278
- Coordination number (CN) 75, 76, 86, 91, 92, 93, 154, 155, 156, 160, 164
- Corresponding activation energies 212
- Coupled cluster (CC) 78, 79, 80
- Crown ethers 77, 94, 95, 96, 97, 100, 101, 103, 104, 106, 124, 125, 126, 127, 128, 134, 135, 146, 147, 159, 163
- Cyanex 111, 112, 113, 130, 131, 164
- Cyclohexylamine 229, 230
- Cysteine 189, 191, 204, 334, 341
- Cytochrome P450s (CYPs) 43, 44
- ## D
- Degrees of freedom (DoF) 28, 269, 278, 288, 296
- Delocalization 310, 311, 316, 317, 332, 336, 337, 338, 339, 340, 344, 345
- Density 77, 78, 81, 82, 83, 84, 91, 111, 120, 121, 129, 161, 314, 315, 316, 317, 318, 329, 333, 336, 338, 339
- electronic 316, 336, 338, 339
  - one-electron 314, 315
- Density functional theory (DFT) 76, 77, 78, 81, 84, 92, 109, 110, 117, 164, 315, 333, 334
- Designing new ligands 75, 76
- Desolvation energies 224, 225, 230, 231, 232, 238, 239, 242

DFT level of theory 134  
DFT properties 335, 336  
Diammine ligands 225  
Diglycolamide 77, 113, 114  
Diglycolamide ligands 113, 131  
Diluents ligand  $\Delta G_{ext}$  149, 150  
Direction, opposite 100, 101  
Distance constraint model (DCM) 278, 296  
Distribution, probability 31, 146, 316  
Docking 8, 9, 11, 19, 23, 26, 27, 28, 29, 31, 32, 33, 35, 36, 37, 41, 44, 45, 47, 49  
  protein-peptide 47, 49  
  rigid 9, 11, 26, 27  
Docking methods 8, 9, 23, 24, 27  
  flexible 9, 27  
  molecular 23, 24, 27  
Docking process 27, 32, 35, 36, 37  
Docking programs 9, 24, 26, 35  
Dodecane phase 116, 140, 141  
Donor atoms 75, 77, 86, 87, 94, 95, 102, 103, 104, 105, 109, 114, 116, 117, 127, 134, 135, 164  
  effect of 103, 134  
Doxorubicin 185, 195, 218, 219, 220, 223, 239, 243  
Drug delivery 189, 194, 195, 196  
Drug discovery process 3, 4, 5, 14, 33, 34, 35, 41, 45  
Drug discovery projects 39, 41, 42, 45  
Drug metabolism 5, 43, 44  
Drug molecules 4, 5, 15, 45  
Drugs, permeability of 221, 234  
Dynamic correlations 290

## E

Efflux, increased 188, 201, 204, 205, 243  
Elastic models, based 285, 286  
Elastic network models (ENMs) 260, 261, 268, 269, 279, 280, 285, 290  
Electromechanical fluidity 231, 233  
Electron affinity (EA) 186, 210, 213, 221, 222, 223, 224, 228, 230, 238, 239, 240, 241, 244  
Electron correlation 77, 78, 79, 81

Electron density 81, 83, 127, 313, 316, 328, 329, 333, 335, 338, 339  
Electron density distribution 314, 317, 325  
Electron distributions 313, 316, 317  
Electronic structure calculations 76, 78, 79, 146, 319, 327  
Electrophilicity 221, 226, 227, 313, 333, 335, 345  
Endocytic recycling compartments (ERC) 199  
Energy 23, 29, 39, 78, 79, 81, 82, 83, 84, 96, 122, 123, 129, 132, 133, 138, 143, 160, 207, 211, 220, 221, 222, 223, 224, 231, 261, 271, 273, 281, 287, 335, 345  
  exchange-correlation 82, 83  
  kinetic 81, 82  
Energy calculations 30, 111, 122, 129, 145, 164  
Energy landscape 262, 263, 264, 288  
Energy transport channels 260, 267, 268, 271, 276  
Enthalpy of interaction 87  
Equilibrium and non-equilibrium simulations 283, 284  
Equilibrium simulations 283, 286, 287, 288  
Experimental structures, absence of 8, 22, 34, 36  
Experiments, protein-ligand docking 25  
Explicit solvation model 139, 140, 141, 149  
Extraction energy 130, 140, 141  
  computed 130  
  computed value of free 140, 141  
  higher 130

## F

Free crown ethers 97, 98, 128  
Free energy calculations 38, 117, 141, 143  
Free energy of complexation 87, 134, 135, 138, 141, 142, 144  
Free energy of Eu<sup>3+</sup> 143, 145  
Free energy of extraction 135, 136, 138, 139, 140, 141, 143, 144, 149  
Free radical species 186, 193, 218, 243

## G

Gaussian network model (GNM) 269, 276, 280, 296

Generalized gradient approximation (GGA) 82, 83, 84, 91  
Genetic optimization for ligand docking (GOLD) 27, 29  
Glutamine 339, 340, 341  
Glutathione 189, 191, 202, 204, 209, 211, 212, 213, 215, 223, 229, 230, 236, 237, 238, 239, 240  
Glycine 339, 340, 341, 342

## H

HB interactions 155, 160  
HCTR1 transporter 185, 234, 235, 236, 243  
Heptaplatin 188, 224, 226, 227  
HF energy 78, 79  
High-throughput docking (HTD) 26, 31  
Histidine 334, 341  
Hydrated metal ions 86, 90, 91, 132  
Hydration energy 122, 123  
Hydration enthalpy 122, 133, 134  
Hydrogen bond (HB) 29, 30, 154, 160, 277, 278  
Hydrolysis products 189, 194, 196, 220, 221, 225, 226, 229, 230, 231, 232, 242  
neutral 225, 226, 231  
Hydrophobic interactions 277  
Hypoxic conditions 193

## I

Information quality scheme, predominant 331, 338, 341, 345  
Information-theoretical space 344  
Information-theoretic measures 315, 316, 327, 332, 333, 334, 335, 336, 341, 345  
Information-theoretic space 315, 318, 320, 324, 325  
Information theory 261, 311, 314, 331  
Information transfer 277, 283, 288, 294  
Interaction cutoffs 273, 274  
Interaction energy 18, 39, 85, 86, 87, 103, 125, 126, 129, 130, 132, 153  
Interaction network 276, 277  
Intraprotein signaling mechanisms 265, 288  
Ionization energies 210, 219, 221, 224, 228, 241  
Ionization potential (IP) 331, 333, 335, 345

Ion-ligand interactions 76, 111  
Isoelectronic series 319, 320  
Isoleucine 340, 341

## L

Lactate 222, 224  
Lanthanides 86, 92, 113, 116  
Ligand-based pharmacophore 21, 45  
Ligand binding 19, 34, 260, 261, 263, 264, 265, 268, 276, 280, 282, 286, 290, 291  
Ligand binding perturbs 264, 294  
Ligand binding residues 277  
Ligand binding sites 8, 14, 280  
Ligand complexation 75, 138  
Ligand conformations 26, 28  
Ligand design 39, 86  
Ligand docking 23, 24  
Ligand exchange reactions 136, 190  
Ligand flexibility 27, 28, 29, 33  
Ligand molecules 9, 23, 25, 30, 35, 49  
Ligand-protein interactions 280, 286  
Ligands 5, 6, 7, 8, 9, 10, 11, 14, 15, 16, 18, 20, 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39, 41, 44, 45, 75, 76, 77, 85, 86, 87, 88, 89, 94, 95, 100, 103, 105, 111, 113, 116, 119, 121, 122, 124, 126, 128, 129, 130, 131, 132, 135, 136, 137, 138, 143, 144, 148, 149, 152, 159, 160, 165, 190, 199, 200, 212, 213, 217, 224, 229, 263, 264, 265, 266, 273, 278, 279, 280, 282, 290  
1,1-cyclobutanedicarboxylate 212  
based 87, 116  
bidentate cyclobutane-1,1-dicarboxylate 224  
bound 28, 36  
carboxylate 190  
chelating 77, 138  
hydroxyl 213, 224  
metal ion-crown ligand/calix-crown 148  
molecular 76  
organophosphorous 111, 130  
organophosphorus 111, 113, 130  
Ligands conformation 26  
Linear response theory (LRT) 268, 279, 296  
Lipophilicity 201, 221, 222, 223, 224, 229, 231, 232, 238, 239, 243



Liposomal drugs 219, 220  
Liposomes 219, 220  
Liquid-liquid extraction (LLE) 120, 146, 152, 159  
Lobaplatin 188, 224, 226, 227  
Local density approximation (LDA) 82  
Lysine 335, 341  
Lysosomes 200, 202, 205

## M

Machine learning tools 281, 282, 283  
Macrocyclic crown ethers 94, 145  
Mean square displacement (MSD) 154, 156, 157  
Metal ion complexation 94, 141, 151  
Metal ion complexes 111, 115, 135, 136  
Metal ion-ligand complexation 133, 138  
Metal ion ligand systems 97  
Metal ions of interest 89, 93  
Metal-ligand 87, 88, 107  
Metal-ligand complexation 133, 134  
Methanol 152, 153, 155, 158, 159, 160, 161  
Methionine 189, 191, 339, 340, 341, 342  
Methionine residues 217, 238  
Modelling ion-ligand complexation mechanism 94  
Molecular descriptors 7, 13  
Molecular dynamics 5, 32, 75, 152, 260, 261, 262, 296, 311  
Molecular dynamics simulations 32, 38, 39  
Molecular fingerprints 15  
Molecular interaction field (MIF) 16, 18  
Molecular modelling 76  
Molecular orbital energies 333  
Molecular orbitals 80, 81  
Molecular structures 12, 15, 16, 120, 311, 312, 339  
Molecular systems 77, 78, 81, 89, 113, 155, 314, 319, 321, 334, 344  
    complex 89, 321  
    small 77, 81  
Molecular volumes 221, 224, 231, 232, 233, 239, 241  
Molecules 323, 324, 325, 326, 327  
    pharmacological 323, 324, 327  
    sulfonamide-type of 325, 326, 327

Monomer 85, 139, 140  
    energy of 85  
Monomer water solvation model, explicit 139, 141  
Monte carlo simulation 261  
MP2 level of theory 104, 123, 128, 129, 134  
Multi linear regression (MLR) 17

## N

Nitrate anion 101, 107, 108, 114, 131, 138, 139, 140, 144  
Nitrate ligands 100  
Nitrobenzene 152, 153, 155, 158, 159, 160, 163  
Non-equilibrium simulations 283, 284  
Normal mode analysis (NMA) 39, 260, 261, 262, 267, 296

## O

Optimized structures of hydrated metal ions 90  
Oxalate ligand, bidentate 224  
Oxaliplatin 188, 189, 191, 192, 196, 198, 199, 200, 201, 205, 206, 207, 217, 218, 224, 225, 226, 227, 240, 242  
    hydrolysis of 199  
Oxaliplatin analogues 201  
Oxygen atoms 107, 108, 155, 215, 236

## P

PAH compounds 148  
P-amino benzoic acid (PABA) 325, 326, 327, 328, 329  
Partial least squares (PLS) 17  
Partition coefficients 76, 88, 121, 145, 146, 147, 148, 312  
    calculated value of 148  
    calculated values of 147, 148  
    value of 145, 147, 148  
PDZ domain protein 284, 287  
Peptides 5, 26, 47, 48, 49, 189, 202, 225, 335  
Perdew, Burke and Enzerhof (PBE) 83, 91  
Perturbation methods 261, 269, 279, 280, 287  
Phenylalanine 340, 341  
Phospha crown 103, 128, 135  
Phosphate groups 232, 235, 237

Phosphatidylserine 185, 216, 218, 243  
Phospholipids 216, 237  
Physicochemical properties 7, 10, 12, 42, 312, 317, 335, 345  
Platino 189, 201, 224, 226, 227  
Plasma membrane 200  
Plasma proteins 189, 190, 191, 219, 226, 229  
  human 196, 227  
Platinum 189, 200, 204, 209, 210, 224  
Polycyclic crown ether (PCE) 121, 147, 164  
Predominant information quality scheme (PIQS) 311, 315, 331, 338, 341, 345, 346  
Principal component analysis 261, 269, 296  
Protein binding 30, 196  
Protein binding site 26, 27  
Protein conformations 31, 295  
Protein data bank (PDB) 13, 31, 272, 334, 345  
Protein dynamics 261, 263, 266, 268, 269, 293  
Protein energy landscape 261, 293  
Protein energy networks (PEN) 291  
Protein environment 225, 335  
Protein families 269, 292, 295  
Protein flexibility 26, 27, 31, 32  
Protein functions 263, 268  
Protein-ligand 9, 23, 25, 27, 29, 30, 31, 32, 35  
  realistic 32  
  stable 32  
Protein-ligand 8, 9, 31, 38, 39, 49  
  predicted 31  
  realistic 38  
Protein-ligand complexes 9, 24, 27, 29, 30, 39  
  possible 27  
Protein-ligand docking 24, 26, 28  
  flexible 28  
Protein-ligand docking programs 9, 26, 37  
Protein-ligand environment 35  
Protein-ligand interactions 8, 22, 23, 25, 283  
  measuring 283  
Protein molecules 14, 31, 35, 36, 37, 269  
  fluctuating 269  
  simulated 37  
Protein-protein interactions 5  
Protein-protein interactions 46  
Protein-protein interfacial residues 49  
Protein receptor 36, 37, 38  
Proteins 4, 14, 22, 23, 35, 36, 202, 211, 226, 227, 242, 266, 334, 345  
  homologues 22, 23

  ligand-binding nonallosteric 266  
  natural 334, 345  
  resistant 202, 211  
  serum 226, 227, 242  
  size and complexity of 35, 36  
  unknown 4, 14  
Protein side chain conformations 27  
Protein solution structures 263  
Protein structure graphs (PSGs) 276, 277, 290  
Protein structure information 293  
Protein structures 14, 22, 34, 36, 47, 261, 267, 269, 270, 272, 277, 278, 279, 282, 286, 292  
  determining 36  
  modeling 34  
  uncomplexed 47  
Protein transporters 197, 234  
Pump-probe molecular dynamics (PPMD) 287

## Q

Quantitative structure activity relationship (QSAR) 7, 16, 17, 18, 19, 41, 43, 44, 45, 311, 312, 344  
Quantitative structure properties relation (QSPR) 41, 311

## R

Radial distribution function (RDF) 76, 91, 92, 154, 155, 156, 158, 160  
Reactive oxygen species (ROS) 192, 195, 202, 210, 212, 213, 216  
Receptor molecule 5, 9, 35, 36, 37  
Release of water molecules 138, 142  
Residue correlations 272, 291  
Residue networks 260, 261, 268, 277, 294  
Residue pairs 272, 281, 283, 292  
Resistance, reversal of 185, 186, 209, 233  
Resistant cells 196, 199, 201, 204, 205, 213, 214, 237, 238  
Restricted Hartree-Fock (RHF) 122, 319, 327  
Reversal of cisplatin resistance 208, 209  
Reversal of resistance to Pt drugs 208, 233  
Reversing drugs 234, 238, 239

## S

Scoring functions 25, 28, 29, 30, 31, 38, 49

Screening charge density (SCD) 146  
Second order effects 234  
Separation factor (SF) 76, 88, 111, 137, 151  
Shannon entropy 284, 310, 313, 315, 316, 329, 335, 336, 337, 338, 339, 342  
Signal transduction pathways 209, 210, 265, 281  
Simulation conformations 273  
Single open-unliganded structure 286  
Solvation energies 122, 135, 139, 140, 142, 143, 221, 224, 226, 231, 232, 241, 242  
Solvation shell, first 122, 132, 154, 155  
Solvent effects 38, 75, 76, 140, 143, 146, 159, 241  
Solvent extraction 75, 76, 77, 85, 88, 152, 164  
Solvent molecules 19, 37, 38, 152, 155, 158, 159, 161, 284  
Species 191, 197, 226  
    dominant 197, 226  
    protein-bound carboplatin 191  
Spilt valence polarization (SVP) 90, 109, 110  
Src Kinase 265, 284, 285  
Sr metal ion 99, 100  
Statistical Coupling Analysis 261, 269, 292, 297  
Stoichiometry 114, 115  
Strontium nitrate 99, 100  
Structural changes 103, 204, 265, 267, 312  
Structural parameters 75, 76, 86, 89, 100, 101, 109, 121  
Structures 5, 6, 7, 8, 9, 10, 12, 13, 14, 20, 22, 23, 25, 32, 35, 36, 37, 38, 39, 41, 44, 45, 49, 77, 88, 89, 90, 92, 95, 101, 103, 105, 108, 109, 110, 114, 116, 119, 120, 134, 135, 138, 141, 142, 151, 152, 155, 164, 227, 238, 240, 241, 262, 268, 272, 273, 274, 279, 285, 286, 287, 289, 312, 313, 316, 317, 329  
    docked 38  
    hydrated 90, 92  
    minimized 273, 274, 287  
    multiple 10, 36  
    optimised 240, 241  
Sulfonamides 319, 325, 326, 327, 328, 330  
Support vector machines (SVM) 14, 18, 281, 282

Surface residues 292  
Systems 81, 82, 86, 87, 146, 314, 319, 331  
    biological 314, 331  
    ionic 319  
    metal-extractant 86, 87  
    real 81, 82, 146

## T

Target binding site 21  
Target proteins 8, 13, 14, 22, 32, 36  
    structure of 8, 22  
Target structures 8, 22, 23, 33, 285  
Thermal correction (TC) 133  
Thermodynamic cycle 135, 136, 139, 141, 144  
Thermodynamic parameters 87, 139, 140, 144  
Threonine 340, 341  
TMDGA ligand 116, 139, 140  
TMD simulations 285, 286  
Toxicity 40, 41, 43, 188, 198  
Trans-anti-trans (TAT) 102, 126  
Trans-membrane pore 185, 232, 234, 235, 238  
Transport, active 186, 197, 208, 230, 232, 233  
Triple zeta valence polarization (TZVP) 90, 109, 110  
Tryptophan 340, 341  
Tumour tissue 188, 193, 194, 195, 219, 229

## V

Validations 4, 14, 45  
Vertex 270, 276

## W

Waals interactions 277, 292, 293  
Waals spheres 288, 289  
Water and methanol 159, 160  
Water/chloroform interface 162, 163

## X

X-ray structure 225, 241



**Zaheer Ul-Haq**

---

Dr. Zaheer Ul-Haq is directing the Computational Chemistry group at the Dr. Panjwani Center for Molecular Medicine and Drug research, University of Karachi. He obtained his PhD under the supervision of Prof. Atta-ur-Rahman and completed his post-doctoral studies with Prof. Bernd M. Rode in Innsbruck, Austria. He is a recipient of Fulbright and Humboldt Fellowship from USA and Germany, respectively. He has published over 100 research articles in top international journals of computational chemistry. His area of interest includes in silico screening and Molecular Dynamics simulation of bio-molecules. He is currently serving as editorial board member to the Journal of Molecular Graphics and Modelling, and Current Computer-Aided Drug Design.



**Jeffrey D. Madura**

---

Jeffrey is the Lambert F. Minucci Endowed Chair in Engineering and Computational Sciences and Professor in the Department of Chemistry and Biochemistry at Duquesne University. He earned a B.A. from Thiel College, a Ph.D. in Physical Chemistry from Purdue University and was a postdoctoral fellow at the University of Houston. His research interests include the development and application of biomolecular simulation software, the study of neurotransmitter transporters, the electronic structure of solid-state materials, and the thermoresponsive behavior of smart polymers. He has published 100+ peer-reviewed papers in physical chemistry and received over \$6M in external research funding. He was a recipient of a Dreyfus Teacher-Scholar Award, was the chair of the ACS COMP Division and is an ACS Fellow. Dr. Madura received the 2014 ACS Pittsburgh Local Section Award. He is a co-author to the textbook titled "General Chemistry: Principles and Modern Applications" as well as a co-author to a physical chemistry solutions manual. He received the Bayer School of Natural and Environmental Sciences and the Duquesne University Presidential Award for Excellence in Scholarship in 2007 and the Bayer School of Natural and Environmental Sciences Award for Excellence in Service in 2004. He is currently co-editor to the Journal of Molecular Graphics and Modelling.